Stockreport

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

TScan Therapeutics, Inc.  (TCRX) 
PDF WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T [Read more]